Gene · 8554
PIAS1: protein inhibitor of activated STAT 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PIAS1: protein inhibitor of activated STAT 1. Genes, record 8554. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/8554
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O75925 | E3 SUMO-protein ligase PIAS1 | 651 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents20
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59680 | O75925 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 1280 | O75925 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 915 | O75925 | Espacenet |
| WO 2025146688 A1 | 2025-07-10 | 1 | O75925 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 915 | O75925 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 1280 | O75925 | Espacenet |
| US 11884978 B2 | 2024-01-30 | 661 | O75925 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 68100 | O75925 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 171071 | O75925 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 8446 | O75925 | Espacenet |
1 to 10 of 20
See all 20 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,276
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PIAS1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 9 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 8 | 2025 |
| P30CA033572 | Cancer Center Support Grant | 5 | 2025 |
| P30CA142543 | UT Southwestern Medical Center Simmons Comprehensive Cancer Center | 5 | 2025 |
| P30CA016059 | Massey Cancer Center - Cancer Center Support Grant | 4 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 4 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 4 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 3 | 2025 |
| P30CA016042 | Cancer Center Support Grant | 3 | 2025 |
| R01CA198279 | Shaping DNA Damage Response Networks Via Histone H2A Variants | 3 | 2025 |
1 to 10 of 1,276Source NIH's project files
See all 1,276 nih grantsPapers1,587
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Charting host structural variations in cervical cancer by long-read sequencing pinpoints a functional deletion in PIAS1. | Genomics | 2026 | 42669360 | PubTator, text mining | PubMed |
| Transcriptomic profiling reveals selective attenuation of interferon-associated inflammatory signaling and induction of metallothioneins by a zinc-containing oral rinse. | Front Immunol | 2026 | 42577366 | PubTator, text mining | PubMed |
| Yorkie/YAP Interactors: Fine-Tuning the Hippo Pathway Output. | Cold Spring Harb Perspect Biol | 2026 | 42575696 | PubTator, text mining | PubMed |
| An Acetylation-Primed SUMOylation Switch Controls RORβ Stability through a p300-SIRT1 Regulatory Axis. | Res Sq | 2026 | 42539049 | PubTator, text mining | PubMed |
| Acetylation-Primed SUMOylation Drives RORβ Turnover via a p300-SIRT1 Regulatory Axis. | bioRxiv | 2026 | 42427505 | PubTator, text mining | PubMed |
| Reprogramming gut microenvironment for the treatment of acute severe ulcerative colitis via a synergistic therapy of necroptosis blockade and organoid transplantation. | Nat Commun | 2026 | 42129174 | PubTator, text mining | PubMed |
| PARP4 ADP-ribosylates PIDD1 to complete a phospho/SUMO/PAR-ylation cascade that orchestrates PIDDosome assembly. | Sci Adv | 2026 | 42054439 | PubTator, text mining | PubMed |
| Identification of small ubiquitin-related modifier (SUMO)-related genes-based biomarkers in Alzheimer's disease based on bioinformatics analysis. | Sci Rep | 2026 | 42009747 | PubTator, text mining | PubMed |
| Targeted immune response gene expression profiles linked with necrosis and mortality in preterm infants with surgical necrotizing enterocolitis. | World J Pediatr Surg | 2026 | 41919181 | PubTator, text mining | PubMed |
| Genetic Influences on Disease-Modifying Therapy Response in Multiple Sclerosis: Current Insights and Future Directions. | Balkan Med J | 2026 | 41918263 | PubTator, text mining | PubMed |
1 to 10 of 1,587
See all 1,587 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/8554
GET https://conductscience.org/api/genes/v1/8554/patents